TACE联合PRFA治疗肝脏恶性肿瘤的临床观察

Clinical observation of the TACE combined with PRFA treatment in malignant hepatic carcinoma

目的探讨经导管动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)联合经皮射频消融(percutaneous radiofrequency ablation,PRFA)治疗肝脏恶性肿瘤(malignant hepatic carcinoma,MHC)的临床价值。方法 48例MHC患者,26例行TACE联合PRFA治疗(联合组),22例行单纯TACE治疗(对照组)。观察两组患者治疗后的近期疗效、并发症和第1、2、3年生存率。结果联合组与对照组近期有效率分别为88.5%、63.6%;联合组与对照组患者术后1、2、3年生存率分别为96.2%:86.4%、84.6%:68.2%、76.9%:36.4%。两组患者术后均无严重并发症发生。结论对于MHC的治疗,TACE联合PRFA较之单纯TACE有更高的近期疗效及远期生存。

Objective To investigate the clinical values of the transcatheter arterial chemoembolization （TACE） combined with percutaneous radiofrequency ablation （PRFA） treatment in malignant hepatic carcino- ma （MHC）. Methods In 48 cases of MHC patients, 26 cases received a combination therapy of TACE and RFA treatment （combination group）, while 22 patients were treated with TACE alone （control group）. Re- sponse rate, complications and 1-, 2-,3-year survival rate were assessed. Results The response rate of combi- nation and control group effect was 88.5% and 63.6% respectively. 1-, 2-and 3 year survival rate after opera- tion in the combination group was 96. 2%, 84. 6%, 76. 9% respectively, and 86.4% , 68. 2%, 36.4% re- spectively in the control group. Patients in both groups had no serious complications occurred. Conclusion For the treatment of the MHC, TACE combined PRFA leads to higher response rate and long-term survival compared with TACE alone.